Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis

Zbigniew M. Szczepiorkowski, Nicholas Bandarenko, Haewon C. Kim, Michael L. Linenberger, Marisa B. Marques, Ravindra Sarode, Joseph Schwartz, Beth H. Shaz, Robert Weinstein, Ashka Wirk, Jeffrey L. Winters

Research output: Contribution to journalArticle

183 Citations (Scopus)

Abstract

The American Society for Apheresis (ASFA) Apheresis Applications Committee is charged with a review and categorization of indications for therapeutic apheresis. This elaborate process had been undertaken every 7 years resulting in three prior publications in 1986, 1993, and 2000 of "The ASFA Special Issues." This article is the integral part of the Fourth ASFA Special Issue. The Fourth ASFA Special Issue is significantly modified in comparison to the previous editions. A new concept of a fact sheet has been introduced. The fact sheet succinctly summarizes the evidence for the use of therapeutic apheresis. A detailed description of the fact sheet is provided. The article consists of 53 fact sheets devoted to each disease entity currently categorized by the ASFA. Categories I, II, and III are defined as previously in the Third Special Issue. However, a few new therapeutic apheresis modalities, not yet approved in the United States or are currently in clinical trials, have been assigned category P (pending) by the ASFA Clinical Categories Subcommittee. The diseases assigned to category IV are discussed in a separate article in this issue.

Original languageEnglish (US)
Pages (from-to)106-175
Number of pages70
JournalJournal of Clinical Apheresis
Volume22
Issue number3
DOIs
StatePublished - Jun 2007

Fingerprint

Blood Component Removal
Evidence-Based Practice
Therapeutic Uses
Guidelines
Publications
Clinical Trials

Keywords

  • Apheresis
  • Categories
  • Evidence based
  • Immunoadsorption
  • Indications
  • Leukocytapheresis
  • Photopheresis
  • Plasma exchange

ASJC Scopus subject areas

  • Hematology

Cite this

Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. / Szczepiorkowski, Zbigniew M.; Bandarenko, Nicholas; Kim, Haewon C.; Linenberger, Michael L.; Marques, Marisa B.; Sarode, Ravindra; Schwartz, Joseph; Shaz, Beth H.; Weinstein, Robert; Wirk, Ashka; Winters, Jeffrey L.

In: Journal of Clinical Apheresis, Vol. 22, No. 3, 06.2007, p. 106-175.

Research output: Contribution to journalArticle

Szczepiorkowski, ZM, Bandarenko, N, Kim, HC, Linenberger, ML, Marques, MB, Sarode, R, Schwartz, J, Shaz, BH, Weinstein, R, Wirk, A & Winters, JL 2007, 'Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis', Journal of Clinical Apheresis, vol. 22, no. 3, pp. 106-175. https://doi.org/10.1002/jca.20129
Szczepiorkowski, Zbigniew M. ; Bandarenko, Nicholas ; Kim, Haewon C. ; Linenberger, Michael L. ; Marques, Marisa B. ; Sarode, Ravindra ; Schwartz, Joseph ; Shaz, Beth H. ; Weinstein, Robert ; Wirk, Ashka ; Winters, Jeffrey L. / Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. In: Journal of Clinical Apheresis. 2007 ; Vol. 22, No. 3. pp. 106-175.
@article{cccb4ec25ebb42ecbdca2269faf8bce1,
title = "Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis",
abstract = "The American Society for Apheresis (ASFA) Apheresis Applications Committee is charged with a review and categorization of indications for therapeutic apheresis. This elaborate process had been undertaken every 7 years resulting in three prior publications in 1986, 1993, and 2000 of {"}The ASFA Special Issues.{"} This article is the integral part of the Fourth ASFA Special Issue. The Fourth ASFA Special Issue is significantly modified in comparison to the previous editions. A new concept of a fact sheet has been introduced. The fact sheet succinctly summarizes the evidence for the use of therapeutic apheresis. A detailed description of the fact sheet is provided. The article consists of 53 fact sheets devoted to each disease entity currently categorized by the ASFA. Categories I, II, and III are defined as previously in the Third Special Issue. However, a few new therapeutic apheresis modalities, not yet approved in the United States or are currently in clinical trials, have been assigned category P (pending) by the ASFA Clinical Categories Subcommittee. The diseases assigned to category IV are discussed in a separate article in this issue.",
keywords = "Apheresis, Categories, Evidence based, Immunoadsorption, Indications, Leukocytapheresis, Photopheresis, Plasma exchange",
author = "Szczepiorkowski, {Zbigniew M.} and Nicholas Bandarenko and Kim, {Haewon C.} and Linenberger, {Michael L.} and Marques, {Marisa B.} and Ravindra Sarode and Joseph Schwartz and Shaz, {Beth H.} and Robert Weinstein and Ashka Wirk and Winters, {Jeffrey L.}",
year = "2007",
month = "6",
doi = "10.1002/jca.20129",
language = "English (US)",
volume = "22",
pages = "106--175",
journal = "Journal of Clinical Apheresis",
issn = "0733-2459",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis

AU - Szczepiorkowski, Zbigniew M.

AU - Bandarenko, Nicholas

AU - Kim, Haewon C.

AU - Linenberger, Michael L.

AU - Marques, Marisa B.

AU - Sarode, Ravindra

AU - Schwartz, Joseph

AU - Shaz, Beth H.

AU - Weinstein, Robert

AU - Wirk, Ashka

AU - Winters, Jeffrey L.

PY - 2007/6

Y1 - 2007/6

N2 - The American Society for Apheresis (ASFA) Apheresis Applications Committee is charged with a review and categorization of indications for therapeutic apheresis. This elaborate process had been undertaken every 7 years resulting in three prior publications in 1986, 1993, and 2000 of "The ASFA Special Issues." This article is the integral part of the Fourth ASFA Special Issue. The Fourth ASFA Special Issue is significantly modified in comparison to the previous editions. A new concept of a fact sheet has been introduced. The fact sheet succinctly summarizes the evidence for the use of therapeutic apheresis. A detailed description of the fact sheet is provided. The article consists of 53 fact sheets devoted to each disease entity currently categorized by the ASFA. Categories I, II, and III are defined as previously in the Third Special Issue. However, a few new therapeutic apheresis modalities, not yet approved in the United States or are currently in clinical trials, have been assigned category P (pending) by the ASFA Clinical Categories Subcommittee. The diseases assigned to category IV are discussed in a separate article in this issue.

AB - The American Society for Apheresis (ASFA) Apheresis Applications Committee is charged with a review and categorization of indications for therapeutic apheresis. This elaborate process had been undertaken every 7 years resulting in three prior publications in 1986, 1993, and 2000 of "The ASFA Special Issues." This article is the integral part of the Fourth ASFA Special Issue. The Fourth ASFA Special Issue is significantly modified in comparison to the previous editions. A new concept of a fact sheet has been introduced. The fact sheet succinctly summarizes the evidence for the use of therapeutic apheresis. A detailed description of the fact sheet is provided. The article consists of 53 fact sheets devoted to each disease entity currently categorized by the ASFA. Categories I, II, and III are defined as previously in the Third Special Issue. However, a few new therapeutic apheresis modalities, not yet approved in the United States or are currently in clinical trials, have been assigned category P (pending) by the ASFA Clinical Categories Subcommittee. The diseases assigned to category IV are discussed in a separate article in this issue.

KW - Apheresis

KW - Categories

KW - Evidence based

KW - Immunoadsorption

KW - Indications

KW - Leukocytapheresis

KW - Photopheresis

KW - Plasma exchange

UR - http://www.scopus.com/inward/record.url?scp=34347408011&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34347408011&partnerID=8YFLogxK

U2 - 10.1002/jca.20129

DO - 10.1002/jca.20129

M3 - Article

C2 - 17394188

AN - SCOPUS:34347408011

VL - 22

SP - 106

EP - 175

JO - Journal of Clinical Apheresis

JF - Journal of Clinical Apheresis

SN - 0733-2459

IS - 3

ER -